Nearly 90% of the variation in height among most human populations can be attributed to DNA. The remainder is due to environmental and lifestyle factors, such as nutrition. Although a few genes have been uncovered through studies of rare, single-gene stature disorders, most do not seem to be associated with height in the general population. Recent advances, including the completion of the HapMap project and the availability of large-scale research tools, enabled the scientists to take a systematic approach to understand how common genetic differences can impact a persons height.
The results of the research team, which also includes co-senior authors Timothy Frayling of the Peninsula Medical School, Exeter and Mark McCarthy of the University of Oxford, spring from data made available in two recent genome-wide association studies of type 2 diabetes. The studies, one led by the Diabetes Genetics Initiative and the other by the Wellcome Trust Case Control Consortium, involved nearly 5,000 patients who generously volunteered DNA samples as well as pertinent clinical information, such as height and weight.
After scrutinizing the initial data, the scientists identified a single letter change known as a single nucleotide polymorphism or SNP in the HMGA2 gene as the most promising result. They collaborated with additional researchers to study this SNP through a second phase of analysis that encompassed nearly 30,000 individuals: adults and children from the Avon Longitudinal Study of Parents and Children (ALSPAC) and the Exeter Family Study of Childhood Health (EFSOCH), European adults taking part in a study of type 2 diabetes risk (UKT2D GCC), Finnish individuals participating in the FINRISK1997 health s
|Contact: Nicole Davis|
Broad Institute of MIT and Harvard